7968569

Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.

Patent infringement action against Natco Pharma Limited asserting U.S. Patent No. 7,968,569. The Natco line of cases settled in December 2015 with volume-limited entry from March 2022 and unlimited entry from January 31, 2026.

Patent infringement action involving ANDA No. 209348; complaint expressly alleged infringement of the '800, '217, '569, '498, '095, '621 and '622 patents. Settled September 17, 2020 with volume-limited license from September 1, 2022 and unlimited from January 31, 2026.

Patent infringement action returned by a Docket Alarm search on U.S. Patent No. 7,968,569. Parties and patent list were not independently confirmed.

Patent infringement action listed for U.S. Patent No. 7,968,569. The related Lotus/Alvogen dispute was resolved by a 2019 settlement; Lotus/Alvogen also filed IPR2018-01714.

Listed in Unified Patents' litigation data for U.S. Patent No. 7,968,569; parties and patents asserted were not independently verified.

Patent infringement action against Sun Pharmaceutical. DrugPatentWatch lists patents-in-suit as 7,465,800; 7,855,217; 7,968,569. Judge Susan D. Wigenton presided.

Patent infringement action listed for U.S. Patent No. 7,968,569.

One of the few actions filed outside the District of New Jersey, asserting U.S. Patent No. 7,968,569 against Mylan.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Patent infringement action; IPWatchdog filing roundup expressly lists 7,968,569 among the asserted patents.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Patent infringement action listed for U.S. Patent No. 7,968,569.

Inter partes review petition by Alvogen Pine Brook LLC et al. against Celgene Corporation regarding U.S. Patent No. 7,968,569. The PTAB denied institution on March 14, 2019.

Antitrust/pay-for-delay litigation challenging Revlimid generic settlements. Patents cited include the Revlimid patent family; on September 29, 2026, the court denied motions to dismiss, finding a plausible pay-for-delay agreement between Celgene and Natco.

Antitrust action against Celgene; patents cited include U.S. Patent No. 7,968,569. Judge Edgardo Ramos presided.

Antitrust action against Celgene concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.